Testosterone Therapy Shows Similar Safety Profile in Trans Individuals With and Without PCOS

This research addresses a critical gap in transgender healthcare by examining whether polycystic ovary syndrome (PCOS) increases cardiovascular risks during testosterone therapy. PCOS affects up to 39% of transgender individuals compared to 13% in the general population, making this question highly relevant for treatment decisions.

Mayo Clinic researchers analyzed medical records of 194 transgender and gender diverse individuals, comparing 62 with PCOS to 132 age-matched controls without PCOS. They tracked cardiovascular risk factors, metabolic parameters, and hormone levels before and after starting testosterone therapy.

The key finding was reassuring: testosterone therapy produced similar metabolic changes in both groups. While individuals with PCOS had higher baseline obesity rates and required more diabetes medications, the actual response to testosterone didn't differ significantly. During treatment, the PCOS group showed slightly higher rates of elevated cholesterol and liver enzymes, but these differences were modest.

For longevity and health optimization, this research suggests that PCOS history shouldn't prevent access to gender-affirming testosterone therapy. However, it reinforces the importance of comprehensive metabolic monitoring for all patients, particularly tracking liver function and lipid profiles. The findings also highlight obesity as a key modifiable risk factor that deserves attention regardless of PCOS status.

This study provides evidence-based guidance for clinicians and patients navigating complex treatment decisions, supporting individualized care approaches that balance gender-affirming treatment goals with cardiovascular health optimization.